MAP2K7 and melanoma: On July 30, 2020, the Food and Drug Administration (FDA) approved atezolizumab (programmed cell death ligand 1 inhibitor) plus vemurafenib (BRAF inhibitor) and cobimetinib (MEK inhibitor) for the treatment of patients with unresectable metastatic BRAF V600 variation melanoma based on the findings from the pivotal phase 3 IMspire150 trial.